Lene Buhl Riis

Medicine & Life Sciences

1. Ulcerative Colitis 100%
2. Inflammatory Bowel Diseases 90%
3. Colorectal Neoplasms 48%
4. Crohn Disease 43%
5. Colitis 33%
6. Leukocyte L1 Antigen Complex 33%
7. Neoplasms 28%
8. Collagenous Sprue 27%
9. Colonic Neoplasms 25%
10. Infliximab 25%
11. MicroRNAs 22%
12. Lymphoid Tissue 22%
13. Lasers 22%
14. Intestinal Neoplasms 18%
15. Inflammation 18%
16. Biopsy 18%
17. Colonoscopy 18%
18. Gene Dosage 16%
19. Epithelial Cells 16%
20. Tumor Necrosis Factor-alpha 16%
21. Telemedicine 15%
22. Mucous Membrane 15%
23. Organoids 15%
24. Therapeutics 14%
25. Denmark 13%
26. Lymph Nodes 13%
27. Neoplasm Metastasis 11%
28. Recurrence 11%
29. Tiopronin 11%
30. Down-Regulation 10%
31. CASP8 and FADD-Like Apoptosis Regulating Protein 10%
32. alpha-Defensins 10%
33. Cohort Studies 10%
34. Endoscopy 10%
35. Biomarkers 10%
36. Systematic Reviews 10%
37. Confidence Intervals 10%
38. Child 9%
39. tocilizumab 9%
40. Pediatrics 9%
41. Regeneration 9%
42. Lipidomics 9%
43. Randomized Controlled Trials 9%
44. Tumor Necrosis Factor Inhibitors 9%
45. Chemical and Drug Induced Liver Injury 9%
46. Tumor-Infiltrating Lymphocytes 8%
47. Intestinal Mucosa 8%
48. Etanercept 8%
49. Endosonography 8%
50. Death Domain Receptors 8%